NEUROSCIENCES INEURODEGENERATIVE AND
NEUROPSYCHIATRIC DISORDERS
Objectives
- Define biomarker, intermediate endpoint, and surrogate endpoint
- Consider how to approach identification and validation of a biomarker or set of markers
for complex diseases in which the pathophysiology is unknown (markers of disease state,
progression, severity, diagnostic and epidemiological issues)
- Evaluate how to identify and validate predictive treatment response biomarkers
- Develop an understanding of:
- the advantages and disadvantages of including biomarkers in clinical trials
- the use of biomarkers to select patient subpopulations for clinical studies and clinical
trials
- statistical and modeling issues for validating biomarkers and surrogate markers for use
in clinical studies and clinical trials
Agenda
| Moderators: |
Linda S. Brady, Ph.D., National Institute of Mental Health
Ira Shoulson, M.D., University of Rochester |
Introduction/Overview of Session Objectives
Linda S. Brady, Ph.D.
Overview of Statistical and Modeling Issues for Evaluating Biomarkers
Scott L. Zeger, Ph.D., Johns Hopkins University School of Hygiene and Public Health
Session I. Neuroimaging Markers
Magnetic Resonance Imaging in Multiple Sclerosis Revealing In Vivo Pathology
Donald W. Paty, M.D., Vancouver Hospital and Health Sciences Center
Novel Brain Imaging Techniques and Drug Development in Schizophrenia
Marc Laruelle, M.D., New York State Psychiatric Institute
Discussant: Mony J. de Leon, Ed.D., New York University School of Medicine
Open Discussion
Break
Session II. Behavioral and Genetic Markers
Biomarkers for Cerebrovascular Diseases
Justin A. Zivin, M.D., Ph.D., University of California, San Diego, School of Medicine
Cognitive Markers of Alzheimer's Disease and Schizophrenia
Richard C. Mohs, Ph.D., Mount Sinai School of Medicine
Biochemical and Neuroendocrine Markers in Psychiatric Disorders
Stanley J. Watson, Jr., M.D., Ph.D., University of Michigan School of Medicine
Linking Genetic Markers to Disease Patterns
Kathleen Merikangas, Ph.D., Yale University
Discussant: Scott L. Zeger, Ph.D.
Open Discussion
Summary of Session Recommendations
Overview
Agenda Registration
Conference Abstracts
Hotel & Travel Selected References
Remote Video Conference Participation Contact
NIH Home Page
|